Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 3 | 2020 | 147 | 0.610 |
Why?
|
| Agrochemicals | 3 | 2020 | 4 | 0.590 |
Why?
|
| Agriculture | 3 | 2020 | 31 | 0.580 |
Why?
|
| Occupational Diseases | 2 | 2015 | 265 | 0.470 |
Why?
|
| Occupational Exposure | 2 | 2015 | 319 | 0.440 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 142 | 0.400 |
Why?
|
| Podocytes | 1 | 2025 | 12 | 0.230 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 38 | 0.230 |
Why?
|
| Extracellular Matrix | 1 | 2025 | 148 | 0.210 |
Why?
|
| Glycoproteins | 1 | 2025 | 189 | 0.210 |
Why?
|
| NAD | 2 | 2023 | 53 | 0.210 |
Why?
|
| Parathyroid Hormone | 1 | 2023 | 44 | 0.190 |
Why?
|
| Phosphates | 1 | 2023 | 103 | 0.190 |
Why?
|
| Chelation Therapy | 1 | 2022 | 2 | 0.180 |
Why?
|
| El Salvador | 3 | 2020 | 4 | 0.180 |
Why?
|
| Pyridinium Compounds | 1 | 2020 | 5 | 0.160 |
Why?
|
| Niacinamide | 1 | 2020 | 32 | 0.160 |
Why?
|
| Stilbenes | 1 | 2020 | 22 | 0.160 |
Why?
|
| Creatinine | 1 | 2020 | 135 | 0.160 |
Why?
|
| Nephritis, Interstitial | 1 | 2020 | 15 | 0.160 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2019 | 9 | 0.150 |
Why?
|
| Angiopoietin-2 | 1 | 2019 | 3 | 0.150 |
Why?
|
| Prevalence | 3 | 2020 | 1439 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2018 | 191 | 0.130 |
Why?
|
| Liver Cirrhosis | 1 | 2019 | 182 | 0.130 |
Why?
|
| Biomarkers | 2 | 2019 | 1476 | 0.130 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 196 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 861 | 0.100 |
Why?
|
| Heart Failure | 1 | 2019 | 948 | 0.090 |
Why?
|
| Middle Aged | 6 | 2020 | 18208 | 0.090 |
Why?
|
| Male | 7 | 2025 | 30953 | 0.080 |
Why?
|
| Adult | 5 | 2022 | 17313 | 0.080 |
Why?
|
| Humans | 10 | 2025 | 64954 | 0.070 |
Why?
|
| Kidney | 2 | 2023 | 450 | 0.070 |
Why?
|
| Risk Factors | 2 | 2015 | 5408 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 120 | 0.070 |
Why?
|
| Female | 6 | 2020 | 33927 | 0.060 |
Why?
|
| Vitronectin | 1 | 2025 | 7 | 0.060 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2025 | 16 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2025 | 98 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 1775 | 0.050 |
Why?
|
| Aged | 4 | 2020 | 14924 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 3305 | 0.050 |
Why?
|
| Glycolysis | 1 | 2023 | 59 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2023 | 77 | 0.050 |
Why?
|
| Edetic Acid | 1 | 2022 | 24 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 222 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2025 | 2188 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2025 | 2152 | 0.040 |
Why?
|
| Homeostasis | 1 | 2023 | 377 | 0.040 |
Why?
|
| Animals | 3 | 2025 | 21292 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 166 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 19 | 0.040 |
Why?
|
| Sodium | 1 | 2019 | 59 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2020 | 739 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 856 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2019 | 136 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 801 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 663 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 128 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 309 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2019 | 279 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1013 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1138 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2019 | 219 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1580 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1255 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 2052 | 0.030 |
Why?
|
| Massachusetts | 1 | 2019 | 2143 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 1383 | 0.020 |
Why?
|
| Mice | 1 | 2025 | 11088 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 5601 | 0.020 |
Why?
|
| Child | 1 | 2020 | 4606 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 6842 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6293 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 5776 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 2702 | 0.020 |
Why?
|